Similar articles

• Pneumocystis carinii pneumonia during dose-dense chemotherapy for breast cancer.

  Tolaney SM, Partridge AH, Sheib RG, Burstein HJ, Winer EP. Tolaney SM, et al. J Clin Oncol. 2006 Nov 20;24(33):5330-1. doi: 10.1200/JCO.2006.08.1083. J Clin Oncol. 2006. PMID: 17114668 No abstract available.
• Long-term assessment of cardiac function after dose-dense and -intense sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) as adjuvant therapy for high risk breast cancer.

  Abu-Khalaf MM, Juneja V, Chung GG, DiGiovanna MP, Sipples R, McGurk M, Zelterman D, Haffty B, Reiss M, Wackers FJ, Lee FA, Burtness BA. Abu-Khalaf MM, et al. Breast Cancer Res Treat. 2007 Sep;104(3):341-9. doi: 10.1007/s10549-006-9413-7. Epub 2006 Oct 19. Breast Cancer Res Treat. 2007. PMID: 17051423
• Dose dense and concurrent trastuzumab for early breast cancer in the elderly.

  Cheema UY, Kalapurakal S, White P, Khan AU. Cheema UY, et al. Clin Oncol (R Coll Radiol). 2011 Sep;23(7):494-5. doi: 10.1016/j.clon.2011.02.015. Epub 2011 Mar 21. Clin Oncol (R Coll Radiol). 2011. PMID: 21420286 No abstract available.
• [Importance of dose intensity in chemotherapy--lessons from adjuvant chemotherapy for early breast cancer].

  Tamura K. Tamura K. Rinsho Ketsueki. 2009 Apr;50(4):276-81. Rinsho Ketsueki. 2009. PMID: 19404020 Review. Japanese. No abstract available.
• High-dose chemotherapy and autologous bone marrow support for breast cancer.

  Peters WP. Peters WP. Important Adv Oncol. 1991:135-50. Important Adv Oncol. 1991. PMID: 1869274 Review. No abstract available.